Bay-arenac Behavioral Health - Medicare Mental Health Clinic in Bay City, MI

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

News Archive

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

Reliv International's first-quarter 2010 net sales decline 4.5%

Reliv International, Inc., a nutrition and direct selling company, today reported that sales and earnings in the first-quarter of 2010 were below last year's first-quarter results, but sales outside of the United States rose during the period.

Neurologist suggests maintaining a headache diary to determine and avoid migraine triggers

If you've ever had a migraine, you know it's different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness.

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

Read more Medical News

› Verified 9 days ago

Clinic/Center in Bay City, MI